Assembly Biosciences (ASMB) announced promising interim results from its ongoing Phase 1a/b study of ABI-1179, an investigational drug which is a long-acting helicase-primase inhibitor for recurrent ...
Assembly Biosciences (ASMB) announced positive interim Phase 1a results in healthy participants from its ongoing Phase 1a/b study of ABI-1179, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results